Evidence map›Paper›PMID 36425900›Full record

ArticleHealth science reports2022

Effect of BNT162b2 mRNA booster vaccination on VO

Hielko Miljoen, Youri Bekhuis, Johan Roeykens, Karim Taha, Rudi Frankinouille, Matthijs Michielsen, Caroline M Van de Heyning, Véronique Cornelissen, Kasper Favere, Sander Eens and 5 more

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Hielko MiljoenDepartment of Cardiology Antwerp University Hospital Antwerp Belgium.ORCID 0000-0001-6568-451X
Youri BekhuisDepartment of Cardiovascular Sciences Cardiology, KU Leuven Leuven Belgium.
Johan RoeykensDepartment of Cardiology Antwerp University Hospital Antwerp Belgium.
Karim TahaDepartment of Cardiovascular Sciences Cardiology, KU Leuven Leuven Belgium.
Rudi FrankinouilleDepartment of Cardiology Antwerp University Hospital Antwerp Belgium.ORCID 0000-0002-7109-9090
Matthijs MichielsenDepartment of Rehabilitation Sciences, Group Rehabilitation in Internal Disorders KU Leuven Leuven Belgium.
Caroline M Van de HeyningDepartment of Cardiology Antwerp University Hospital Antwerp Belgium.
Véronique CornelissenDepartment of Rehabilitation Sciences, Group Rehabilitation in Internal Disorders KU Leuven Leuven Belgium.
Kasper FavereDepartment of Medicine and Health Sciences University of Antwerp Antwerp Belgium.ORCID 0000-0003-1848-3701
Sander EensDepartment of Medicine and Health Sciences University of Antwerp Antwerp Belgium.
Jan GielenDepartment of Medicine and Health Sciences University of Antwerp Antwerp Belgium.
Kaatje GoetschalckxDepartment of Cardiovascular Diseases University Hospitals Leuven Leuven Belgium.
Hein HeidbuchelDepartment of Cardiology Antwerp University Hospital Antwerp Belgium.
Guido ClaessenDepartment of Cardiovascular Sciences Cardiology, KU Leuven Leuven Belgium.
Covivax Study Group
University of Antwerp · BEKU Leuven · BEHasselt University · BEUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The goal of the present study was to systematically evaluate the effect of a booster vaccination with the BNT162b2 messenger RNA (mRNA; Pfizer-BioNTech®) vaccine on maximum oxygen uptake (VO Methods: Recreational athletes who were scheduled to undergo booster vaccination were evaluated with transthoracic echocardiography, serum measurements of high-sensitivity C-reactive protein(hsCRP) and high-sensitivity troponin I, and a bicycle cardiopulmonary exercise test (CPET) with serum lactate evaluation before the booster vaccine administration. Seven days postvaccination the test battery was repeated. Additionally, the subjects were asked to fill in a questionnaire on side effects and a subjective evaluation of their relative training volume and intensity as compared to the weeks before vaccination. Results: A group of 42 analysed athletes showed a statistically significant 2.7% decrease in VO Conclusion: In our population of recreational endurance athletes, booster vaccination with the BNT162b2 mRNA vaccine resulted in a statistically significant decrease in VO

Indexed as

athleteCOVID‐19SARS‐CoV‐2vaccinationVO2max

Identifiers

PMID36425900
PMCPMC9679380
OpenAlexW4309734353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.